研究者業績

Katsutoshi Yuasa

  (湯浅 勝敏)

Profile Information

Affiliation
Faculty of PharmacyDepartment of Pharmaceutical Sciences, Musashino University
Degree
博士(薬学)

J-GLOBAL ID
201901012307552675
researchmap Member ID
B000352961

Papers

 32
  • Misa Tokorodani, Hirona Ichikawa, Katsutoshi Yuasa, Tetsuyuki Takahashi, Takao Hijikata
    Biological and Pharmaceutical Bulletin, 43(11) 1715-1728, Nov 1, 2020  Peer-reviewed
  • Katsutoshi Yuasa, Takao Hijikata
    GENES TO CELLS, 21(1) 25-40, Jan, 2016  Peer-reviewed
    We previously identified a distal regulatory element located approximately 5.5-kb upstream of the signal transducer and activator of transcription 1 (STAT1) gene, thereafter designating it as 5.5-kb upstream regulatory region (5.5URR). In this study, we investigated the functional roles of 5.5URR in the transcriptional regulation of STAT1 gene. A chromosome conformation capture assay indicated physical interaction of 5.5URR with the STAT1 core promoter. In luciferase reporter assays, 5.5URR-combined STAT1 core promoter exhibited significant increase in reporter activity enhanced by forced STAT1 expression or interferon (IFN) treatment, but STAT1 core promoter alone did not. The 5.5URR contained IFN-stimulated response element and GAS sites, which bound STAT1 complexes in electrophoretic mobility shift assays. Consistently, chromatin immunoprecipitation (ChIP) assays of HEK293 cells with Halo-tagged STAT1 expression indicated the association of Halo-tagged STAT1 with 5.5URR. ChIP assays with IFN treatment demonstrated that IFNs promoted the recruitment of Halo-tagged STAT1 to 5.5URR. Forced STAT1 expression or IFN treatment increased the expression of endogenous STAT1 and other IFN signaling pathway components, such as STAT2, IRF9 and IRF1, besides IFN-responsive genes. Collectively, the results suggest that 5.5URR may provide a regulatory platform for positive feedback control of STAT1 expression possibly to amplify or sustain the intracellular IFN signals.
  • Katsutoshi Yuasa, Natsumi Aoki, Takao Hijikata
    EXPERIMENTAL CELL RESEARCH, 336(2) 287-297, Aug, 2015  Peer-reviewed
    Single-nucleotide polymorphisms associated with type 2 diabetes (T2D) have been identified in Jazf1, which is also involved in the oncogenesis of endometrial stromal tumors. To understand how Jazf1 variants confer a risk of tumorigenesis and T2D, we explored the functional roles of JAZF1 and searched for JAZF1 target genes in myogenic C2C12 cells. Consistent with an increase of Jazf1 transcripts during myoblast proliferation and their decrease during myogenic differentiation in regenerating skeletal muscle, JAZF1 overexpression promoted cell proliferation, whereas it retarded myogenic differentiation. Examination of myogenic genes revealed that JAZF1 overexpression transcriptionally repressed MEF2C and MRF4 and their downstream genes. AMP deaminase1 (AMPD1) was identified as a candidate for JAZF1 target by gene array analysis. However, promoter assays of Ampd1 demonstrated that mutation of the putative binding site for the TR4/JAZF1 complex did not alleviate the repressive effects of JAZF1 on promoter activity. Instead, JAZF1-mediated repression of Ampd1 occurred through the MEF2-binding site and E-box within the Ampd1 proximal regulatory elements. Consistently, MEF2C and MRF4 expression enhanced Ampd1 promoter activity. AMPD1 overexpression and JAZF1 downregulation impaired AMPK phosphorylation, while JAZF1 overexpression also reduced it. Collectively, these results suggest that aberrant JAZF1 expression contributes to the oncogenesis and T2D pathogenesis. (C) 2015 Elsevier Inc. All rights reserved.
  • Akinori Nakamura, Masanori Kobayashi, Mutsuki Kuraoka, Katsutoshi Yuasa, Naoko Yugeta, Takashi Okada, Shin'ichi Takeda
    SCIENTIFIC REPORTS, 3 2183, Jul, 2013  Peer-reviewed
    The molecular mechanism of muscle degeneration in a lethal muscle disorder Duchene muscular dystrophy (DMD) has not been fully elucidated. The dystrophic dog, a model of DMD, shows a high mortality rate with a marked increase in serum creatine kinase (CK) levels in the neonatal period. By measuring serum CK levels in cord and venous blood, we found initial pulmonary respiration resulted in massive diaphragm damage in the neonates and thereby lead to the high serum CK levels. Furthermore, molecular biological techniques revealed that osteopontin was prominently upregulated in the dystrophic diaphragm prior to the respiration, and that immediate-early genes (c-fos and egr-1) and inflammation/immune response genes (IL-6, IL-8, COX-2, and selectin E) were distinctly overexpressed after the damage by the respiration. Hence, we segregated dystrophic phases at the molecular level before and after mechanical damage. These molecules could be biomarkers of muscle damage and potential targets in pharmaceutical therapies.
  • Eiji Tominaga, Katsutoshi Yuasa, Sho Shimazaki, Takao Hijikata
    EXPERIMENTAL CELL RESEARCH, 319(3) 77-88, Feb, 2013  Peer-reviewed
    MicroRNA-1 (miR-1) has recently been suggested to function as a tumor suppressor. Its functional relevance was assessed by exploring structural and tumorigenic properties of lung cancer A549 cells stably transduced with retrovirus containing pre-miR-1. A549 cells over-expressing miR-1 exhibited a significant morphological change from a mesenchymal to an epithelial phenotype characterized by cell polarization and intercellular junctions. The cells showed increased expression of E-cadherin, which colocalized with cortical actin filaments and vinculin to form typical adherens junction at the apical regions of intercellular borders. Additionally, they exhibited occludin-positive tight junctions at similar apical regions. Moreover, their migratory and invasive activities were inhibited, and their sensitivity to doxorubicin was increased slightly compared to control mock-infected cells. These structural and tumorigenic properties induced by miR-1 were associated with the reduced expression of Slug, which was a transcriptional repressor of E-cadherin or an inducer of epithelial-to-mesenchymal transition. Consistently, Slug was identified as a miR-1 target by bioinformatics and a luciferase reporter assay with plasmids containing luciferase-Slug 3'UTR. Collectively, the data presented here suggest that re-expression of miR-1 may be an effective therapy that prevents cancer malignancy by converting cells from a mesenchymal phenotype to an epithelial phenotype via the downregulation of Slug. (c) 2012 Elsevier Inc. All rights reserved.

Misc.

 5
  • Yuasa Katsutoshi, Hijikata Takao, Takeda Shin'ichi
    Drug Delivery System, 22(2) 140-147, 2007  
    Muscular dystrophies are progressive muscle-wasting diseases often caused by defects of genes encoding sarcolemmal or sarcolemma-associated proteins and their consequential deficiency in muscle. For the muscular dystrophies, gene therapy has been widely studied, and several strategies involving the use of viral vector-mediated delivery have been developed to restore partial expression of deficient proteins. However, systemic, specific and safe delivery of therapeutic genes to skeletal muscles remains major hurdles for the clinical application of those strategies.<BR>In this review, we first introduce genetic backgrounds and pathogenesis of muscular dystrophies and then some strategies of gene therapy, undertaken for potential treatment of muscular dystrophies. Furthermore, we describe and discuss current chemical and biological methods to carry therapeutic materials including oligonucleotides and cDNAs into individual muscle fibers and to deliver them to the musculature of the whole body.
  • 荒木 亘, 湯浅 勝敏, 武田 伸一, 城谷 圭朗, 高橋 慶吉, 田平 武
    神経化学, 38(3) 266-266, Sep, 1999  
  • 武田伸一, 湯浅勝敏
    内科, 81 354-356, 1998  
  • 湯浅勝敏,石井亜紀子,宮越友子,武田伸一
    日本臨床, 55 3148-3153, 1997  
  • 杉山政則, 湯浅勝敏, 熊谷孝則, 木下英司, 松尾裕彰, 西村基弘, 鈴木康司
    臨床病理, 43 765-771, 1995  

Research Projects

 1